title: Do we still need chemotherapy for AIDS-associated Kaposi's sarcoma?
abstract: The widespread introduction of effective combination antiretroviral therapy (cART) has had a major influence on the epidemiology and natural history of AIDS-associated Kaposi's sarcoma (AIDS-KS). cART has reduced the incidence of AIDS-KS, and it has been shown to be an effective treatment for early-stage KS. So with the widespread availability of cART, is systemic chemotherapy still required for AIDS-KS? Two indications appear to remain: advanced-stage AIDS-KS and patients who have progressive KS despite effective cART including immune reconstitution inflammatory syndrome KS.
authors: National Centre for HIV Malignancy, Chelsea & Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK.
authors: Alessia
authors: A
authors: Dalla Pria
authors: Katy
authors: K
authors: Hayward
authors: Mark
authors: M
authors: Bower
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000401:mortality; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000188:drug therapy; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000401:mortality; D016896:Treatment Outcome
chemical_list: D044966:Anti-Retroviral Agents